Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2022 Oct 14

PMID 36231661

Authors

Gyeyoung Choi

Gyeongseon Shin

SeungJin Bae

Affiliations

Soon will be listed here.

Abstract

Although chimeric antigen receptor (CAR) T-cell therapy has shown a high response rate in lymphoma patients, its cost-effectiveness is controversial due to the high price and uncertainty of the clinical evidence. In addition to the high acquisition cost of CAR T-cell therapy, procedure and facility cost increase the financial burden considering the frequency of adverse events such as cytokine release syndrome. In clinical research, relatively short follow-up periods were used compared to traditional cancer agents. In addition, head-to-head comparative effectiveness data are unavailable, which is an important factor when evaluating the cost-effectiveness of a new treatment. Additional evidence that will compensate for the uncertainty of existing clinical data is needed for full evaluation of long-term efficacy, safety, and comparative effectiveness.

Citing Articles

The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment.

Guo Q, Li J, Wang J, Li L, Wei J, Zhang L Front Pharmacol. 2024; 15:1502298.

PMID: 39734406 PMC: 11672202. DOI: 10.3389/fphar.2024.1502298.

Emerging approaches for T cell-stimulating platform development.

Ariail E, Garcia Espinoza N, Stephenson A, Spangler J Cell Syst. 2024; 15(12):1198-1208.

PMID: 39701036 PMC: 11665896. DOI: 10.1016/j.cels.2024.11.007.

Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy.

Zhang S, Peng L, Chen Y, Xu Y, Moradi V Inflamm Regen. 2024; 44(1):45.

PMID: 39490997 PMC: 11533312. DOI: 10.1186/s41232-024-00358-x.

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.

Hansen D, Lu X, Castaneda Puglianini O, Sorensen S, Usmani S, Zhang E Front Immunol. 2024; 15:1408892.

PMID: 39234256 PMC: 11372240. DOI: 10.3389/fimmu.2024.1408892.

The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.

Anurogo D, Luthfiana D, Anripa N, Fauziah A, Soleha M, Rahmah L Adv Pharm Bull. 2024; 14(2):314-330.

PMID: 39206402 PMC: 11347730. DOI: 10.34172/apb.2024.034.

References

Bishop M, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N . Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021; 386(7):629-639. DOI: 10.1056/NEJMoa2116596. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Dotti G, Gottschalk S, Savoldo B, Brenner M . Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2013; 257(1):107-26. PMC: 3874724. DOI: 10.1111/imr.12131. View

Brudno J, Kochenderfer J . Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017; 15(1):31-46. DOI: 10.1038/nrclinonc.2017.128. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

Roth J, Sullivan S, Lin V, Bansal A, Purdum A, Navale L . Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018; 21(12):1238-1245. DOI: 10.1080/13696998.2018.1529674. View

Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz C . Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017; 9(9):1183-1197. PMC: 5582407. DOI: 10.15252/emmm.201607485. View

Petrou P . Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. Expert Rev Pharmacoecon Outcomes Res. 2019; 19(5):529-536. DOI: 10.1080/14737167.2019.1651646. View

10.

Lyman G, Nguyen A, Snyder S, Gitlin M, Chung K . Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. JAMA Netw Open. 2020; 3(4):e202072. PMC: 7136832. DOI: 10.1001/jamanetworkopen.2020.2072. View

11.

Whittington M, McQueen R, Campbell J . Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications. J Clin Oncol. 2019; 38(4):359-366. DOI: 10.1200/JCO.19.01558. View

12.

Whittington M, McQueen R, Ollendorf D, Kumar V, Chapman R, Tice J . Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr. 2018; 172(12):1161-1168. PMC: 6583018. DOI: 10.1001/jamapediatrics.2018.2530. View

13.

Sarkar R, Gloude N, Schiff D, Murphy J . Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2018; 111(7):719-726. PMC: 6624167. DOI: 10.1093/jnci/djy193. View

14.

Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B . KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020; 382(14):1331-1342. PMC: 7731441. DOI: 10.1056/NEJMoa1914347. View

15.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

16.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

17.

Shah B, Ghobadi A, Oluwole O, Logan A, Boissel N, Cassaday R . KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502. PMC: 11613962. DOI: 10.1016/S0140-6736(21)01222-8. View

18.

Neelapu S, Dickinson M, Munoz J, Ulrickson M, Thieblemont C, Oluwole O . Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022; 28(4):735-742. PMC: 9018426. DOI: 10.1038/s41591-022-01731-4. View

19.

Fiorenza S, Ritchie D, Ramsey S, Turtle C, Roth J . Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 2020; 55(9):1706-1715. DOI: 10.1038/s41409-020-0956-8. View

20.

Hernandez I, Prasad V, Gellad W . Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncol. 2018; 4(7):994-996. PMC: 6145722. DOI: 10.1001/jamaoncol.2018.0977. View